Treatment with GM-CSF Secreting Myeloid Leukemia Cell Vaccine Prior to Autologous-BMT Improves the Survival of Leukemia-Challenged Mice

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 330-340

  Zilberberg, Jenny ^a   Friedman, Thea M ^a   Dranoff, Glenn ^b   Korngold, Robert ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

AML; Autologous BMT; Immunotherapy

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER IMMUNIZATION; CANCER SURVIVAL; CONTROLLED STUDY; LEUKEMIA CELL; LYMPHOCYTE; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN;

ADAPTIVE IMMUNITY; ANIMALS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; CELL LINE, TUMOR; GENES, REPORTER; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNITY, CELLULAR; INJECTIONS, INTRAPERITONEAL; LEUKEMIA, MYELOID; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 79551682330     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.09.020     Document Type: Article

References (38)

1. Gocheva L.B. Nonmyeloablative conditioning regimens and bone marrow transplantation-some contemporary aspects. Folia Med (Plovdiv) 2010, 52:12-17.
2. Hogan W.J., Deeg H.J. Stem cell transplantation: graft-mediated antileukemia effects. Methods Mol Med 2005, 109:421-444.
3. Parker C.J., Brodsky R.A., Levine J.E. Treatment versus transplant for challenging hematologic disorders. Biol Blood Marrow Transplant 2009, 15:72-78.
4. Ferrara J.L., Deeg H.J. Graft-versus-host disease. N Engl J Med 1991, 324:667-674.
5. Korngold R. Biology of graft-versus-host disease. Am J Pediatr Hematol Oncol 1993, 15:18-27.
6. Reddy P., Arora M., Guimond M., Mackall C.L. GVHD: a continuing barrier to the safety of allogeneic transplantation. Biol Blood Marrow Transplant 2009, 15:162-168.
7. Borrello I.M., Levitsky H.I., Stock W., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009, 114:1736-1745.
8. Dunussi-Joannopoulos K., Dranoff G., Weinstein H.J., Ferrara J.L., Bierer B.E., Croop J.M. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998, 91:222-230.
9. Teshima T., Liu C., Lowler K.P., Dranoff G., Ferrara J.L. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res 2002, 62:796-800.
10. Teshima T., Mach N., Hill G.R., et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 2001, 61:162-171.
11. Borrello I., Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002, 13:185-193.
12. Ho V.T., Vanneman M., Kim H., et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 2009, 106:15825-15830.
13. Borrello I., Sotomayor E.M., Rattis F.M., Cooke S.K., Gu L., Levitsky H.I. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000, 95:3011-3019.
14. Guillaume T., Rubinstein D.B., Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998, 92:1471-1490.
15. Hsieh M.H., Korngold R. Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 2000, 96:1047-1055.
16. Friedman T.M., Jones S.C., Statton D., Murphy G.F., Korngold R. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens. Biol Blood Marrow Transplant 2004, 10:224-235.
17. Korngold R., Leighton C., Manser T. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 1994, 58:278-287.
18. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993, 90:3539-3543.
19. Logan B.R., Zhang M.J., Klein J.P. Regression models for hazard rates versus cumulative incidence probabilities in hematopoietic cell transplantation data. Biol Blood Marrow Transplant 2006, 12:107-112.
20. Logan B.R., Klein J.P., Zhang M.J. Comparing treatments in the presence of crossing survival curves: an application to bone marrow transplantation. Biometrics 2008, 64:733-740.
21. Khan A.R., Dovedi S.J., Wilkinson R.W., Pritchard D.I. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy. Int Rev Immunol 2010, 29:461-484.
22. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
23. Mach N., Gillessen S., Wilson S.B., Sheehan C., Mihm M., Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000, 60:3239-3246.
24. Bosco N., Swee L.K., Benard A., Ceredig R., Rolink A. Auto-reconstitution of the T-cell compartment by radioresistant hematopoietic cells following lethal irradiation and bone marrow transplantation. Exp Hematol 2010, 38. 222-232, e222.
25. Anderson B.E., McNiff J.M., Matte C., Athanasiadis I., Shlomchik W.D., Shlomchik M.J. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004, 104:1565-1573.
26. Sallusto F., Lanzavecchia A. Exploring pathways for memory T cell generation. J Clin Invest 2001, 108:805-806.
27. Woodland D.L., Kohlmeier J.E. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009, 9:153-161.
28. Badovinac V.P., Harty J.T. Memory lanes. Nat Immunol 2003, 4:212-213.
29. Zilberberg J., McElhaugh D., Gichuru L.N., Korngold R., Friedman T.M. Inter-strain tissue-infiltrating T cell responses to minor histocompatibility antigens involved in graft-versus-host disease as determined by Vbeta spectratype analysis. J Immunol 2008, 180:5352-5359.
30. Itano A.A., McSorley S.J., Reinhardt R.L., et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003, 19:47-57.
31. Lenz A., Heine M., Schuler G., Romani N. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 1993, 92:2587-2596.
32. Romani N., Clausen B.E., Stoitzner P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev 2010, 234:120-141.
33. Merad M., Manz M.G., Karsunky H., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002, 3:1135-1141.
34. Holt P.G., Haining S., Nelson D.J., Sedgwick J.D. Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of the conducting airways. J Immunol 1994, 153:256-261.
35. Ruedl C., Koebel P., Bachmann M., Hess M., Karjalainen K. Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J Immunol 2000, 165:4910-4916.
36. Diao J., Winter E., Chen W., Xu F., Cattral M.S. Antigen transmission by replicating antigen-bearing dendritic cells. J Immunol 2007, 179:2713-2721.
37. Romani N., Thurnher M., Idoyaga J., Steinman R.M., Flacher V. Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol 2010, 88:424-430.
38. Simons J.W., Jaffee E.M., Weber C.E., et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997, 57:1537-1546.